PeptideStack
5.2kquestions
20kanswers
220users

What does a payer want to see before approving liraglutide?

Asked 14 May 2026Modified 13 days agoViewed 3.4k times
19

I have the plan documents and the written criteria, which took two calls to obtain.

I want a method I can write down and repeat, not a rule of thumb.

I would rather over-engineer this than discover a problem later, within reason.

Which parts of this are load-bearing and which parts are habit?

prior-authorization
prior-authorization

Prior authorisation mechanics: medical-necessity criteria, documenting a lifestyle-intervention requirement, step therapy, and the…

19 questions
insurance
insurance

Coverage: formulary tiers, exclusion versus non-coverage, the difference a diabetes indication makes, employer carve-outs, and what an appeal…

35 questions
t2dm
t2dm

Type 2 diabetes: glycaemic endpoints, the SURPASS and SUSTAIN programmes, dose ranges licensed for diabetes versus obesity, and interaction with…

22 questions
liraglutide
liraglutide

A once-daily GLP-1 receptor agonist and the compound that established the class. Still relevant for its shorter half-life, its paediatric and…

235 questions
shareeditfollowflag
MM
askedmg_per_ml15k1614 May 2026

4 Answers

Accepted answer first, then by votes
36

Accepted answer

The short version: get the criteria, evidence each one in the record, submit with the documentation attached, and appeal a denial with the reason addressed.

Obtain the medical policy for the specific drug and plan first. It lists the required diagnosis codes, thresholds, documented durations and any prerequisite therapy, and it is the checklist the reviewer works from.

Twelve-month cost model, illustrative structure

LineBrand, insuredCompounded, subscriptionResearch-grade, self-tested
ProductCopay × 12Monthly fee × 12Vials × unit price
ConsultationCovered or copayBundledNot applicable
Monitoring labsOften coveredUsually notSelf-funded
Independent testingNot applicableOptionalEssential; per lot
ShippingPharmacyIncludedPer order
Dominant costCopay structureSubscription feeTesting

Stated carefully, where prerequisite therapy is required, the record needs the agent, the dates, the dose and the reason it was stopped. "Tried and failed" without those four elements is not documentation.

Medical policies stating prior-authorisation criteria are published by plans and are obtainable before submission.

Get the criteria first. A request written blind is a request written badly.

shareimprove this answerflag
TM
answered · acceptedtwo_two_micron9.3k1617 Jul 2026
2Sharing records with the usual clinician is the advice I ignored and should not have. – ivo_paunovic 6 months ago
add a comment
Sponsored

Sigma-Aldrich - Certified Reference Materials

Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.

Shop standards
41

Answering this needs the plan, since criteria vary and a general answer is not actionable.

The denial letter states a specific reason. The appeal should address that reason first and explicitly, with the missing evidence attached, rather than restating the original case.

Track the deadlines. Appeal windows are finite, and a well-founded appeal filed late is worth nothing at all.

Appeal windows and renewal periods are defined in plan documents and are strictly applied.

The denial reason is the appeal specification. Address it directly.

shareimprove this answerflag
DO
answeredDr_Malik_Osei19k2718 Jun 2026
28

The relevant point is that most denials cite a missing element rather than a clinical disagreement, and missing elements are fixable.

Each criterion must be evidenced in the clinical record, dated, before the request. A criterion asserted in a covering letter but absent from the notes is the commonest reason for a denial.

Submit the supporting documents with the request rather than waiting to be asked. Requests denied for insufficient information are denials that a complete submission would have avoided.

Attach everything on the first submission. Incomplete is the commonest denial.

edited 1 Jun 2026 by harriet_lonsdale — added the method parameters

shareimprove this answerflag
HL
answeredharriet_lonsdale35k13825 May 2026
16

The denial letter states the reason. That reason is the specification for the appeal.

A peer-to-peer review — the prescriber speaking to the plan's reviewer — is available in many systems and resolves a meaningful proportion of denials that a written appeal would not.

Evidence every criterion in the dated record, not in a covering letter.

shareimprove this answerflag
FV
answeredfill_volume22k3823 Jun 2026
5The indication mattering more than the molecule is the part people find hardest to believe. – marta_okonkwo 5 months ago
4The registration-check suggestion is the one verifiable thing in this whole area. – lane_transit 3 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.